Saint Luke's Research

Saint Luke's Research

Advancing patient care and population health through innovative research

Research has been the heart of Saint Luke’s for more than 135 years. Saint Luke’s Research strives to continuously improve the quality and value of health care as a national leader in clinical, translational, and outcomes research. Our mission is to advance the prevention and treatment of disease, helping patients live healthier and longer lives.

Saint Luke’s Office of Research Services works with Saint Luke’s affiliated researchers across the health system to make research more effective by assisting with planning, implementation, and logistics. Research Services offers the support infrastructure to further strengthen Saint Luke’s role as a national leader in research.



Provides a centralized and comprehensive infrastructure for research at Saint Luke’s.

Learn more


Saint Luke’s physicians within our institutes participate in industry-leading research.


Research studies at Saint Luke’s need participants of all ages and backgrounds.

Browse current studies

Support advanced research

Donor generosity enables our health system to investigate, identify, and provide the safest, innovative technologies and state-of-the-art treatments possible to patients now and for generations to come. Create a healthier tomorrow by investing in clinical research today.


Saint Luke's Mid America Heart Institute
PRESERVED-HF trial findings on the substantial impact of dapagliflozin in individuals with heart failure with preserved ejection fraction (HFpEF) published in Nature Medicine
The findings of the PRESERVED-HF trial, offering potential new hope for people struggling with heart failure with preserved ejection fraction (HFpEF), are published in the journal, Nature Medicine.
Healio: DARE-19: Dapagliflozin well-tolerated for inpatient COVID-19 with, without diabetes
The SGLT2 inhibitor dapagliflozin is well-tolerated in adults hospitalized with COVID-19, regardless of diabetes status, according to new analyses from the DARE-19 trial.
Saint Luke’s Researchers Again Take Center Stage at Global Cardiology Conference
Saint Luke’s Mid America Heart Institute to share detailed trial results at American College of Cardiology Scientific Session May 15-17.
New Research Suggests Magnesium and Vitamin D Can Help Reduce COVID-19 Infections
The impact of COVID-19 varies dramatically between individuals due to variability in the immune system’s ability to fight it. For many, a simple strategy to bolster immunity is to get magnesium and vitamin D levels back into the optimal range.
New Clinical Trial for Heart Failure Tests Patients Remotely Using Wearable Devices
The world's first decentralized, digitally driven medical study has patients wear smart watches to record the effects of a heart failure medication.